Eva Corey
YOU?
Author Swipe
View article: CDC7 is a targetable regulator of advanced prostate cancer
CDC7 is a targetable regulator of advanced prostate cancer Open
Prostate cancer is estimated to contribute to over 35,000 deaths of men residing in the United States, with the majority fatality due to metastatic disease. CDC7 is a kinase that regulates DNA replication and is found elevated during neuro…
View article: The Olive Phenolic S–(–)–Oleocanthal as a Novel Intervention for Neuroendocrine Prostate Cancers: Therapeutic and Molecular Insights
The Olive Phenolic S–(–)–Oleocanthal as a Novel Intervention for Neuroendocrine Prostate Cancers: Therapeutic and Molecular Insights Open
Background/Objectives. Prostate cancer (PCa) is among the leading causes of death from cancer in men. Frequent use of androgen receptor inhibitors induces PCa transdifferentiation, leading to poorly differentiated neuroendocrine PCa (NEPC)…
View article: BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction Open
BPTF, the scaffolding subunit of the nucleosome remodeling factor (NURF) complex, has been implicated in the progression of several malignancies, but its role in prostate cancer (PCa) remains unclear. Here, we demonstrate that BPTF is upre…
View article: Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer
Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer Open
Wnt signaling is a complex pathway consisting of numerous ligands and frizzled (FZD) receptors. These signaling components are widely expressed in human prostate tissues and often undergo upregulation or mutation in advanced prostate cance…
View article: Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target
Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target Open
Epigenetic and transcriptional dysregulation plays a fundamental role in tumor lineage plasticity (LP). However, the underlying mechanisms, especially for the initial events of LP development, are still poorly understood. Here, we report t…
View article: Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies Open
Genomic loss of the transcriptional kinase CDK12 occurs in ∼6% of metastatic castration-resistant prostate cancers (mCRPC) and correlates with poor patient outcomes. Prior studies demonstrate that acute CDK12 loss confers a homologous reco…
View article: Disrupting the interaction between androgen receptor and its coregulator WDR77 delays the growth of treatment-resistant prostate cancer
Disrupting the interaction between androgen receptor and its coregulator WDR77 delays the growth of treatment-resistant prostate cancer Open
Continued reliance on the androgen receptor (AR) after androgen deprivation therapy (ADT) fails causes 35,000 American prostate cancer (CaP) deaths annually. Targeting the AR's transcriptional activity could overcome this acquired resistan…
View article: TRIM24 Degradation Counteracts Adaptation to Androgen Receptor Inhibition in Prostate Cancer
TRIM24 Degradation Counteracts Adaptation to Androgen Receptor Inhibition in Prostate Cancer Open
The androgen receptor (AR) is the primary therapeutic target in prostate cancer. While androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSi) are effective, the disease eventually progresses to fatal castratio…
View article: FOXJ1 mediates taxane resistance through regulation of microtubule dynamics
FOXJ1 mediates taxane resistance through regulation of microtubule dynamics Open
Docetaxel is the first-line chemotherapy for metastatic castration-resistant prostate cancer (PC), but clinically meaningful mechanisms of resistance remain to be established. We generated an in vivo model of docetaxel resistance using cas…
View article: Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate Cancer
Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate Cancer Open
Extrachromosomal DNAs (ecDNAs), which replicate and segregate in a non-Mendelian manner, serve as vectors for accelerated tumor evolution. By integrating chromatin accessibility, whole-genome sequencing, and Hi-C-based genome topology data…
View article: BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer
BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer Open
A subgroup (~20%-30%) of castration-resistant prostate cancer (CRPC) aberrantly expresses a gastrointestinal (GI) transcriptome governed by 2 GI-lineage-restricted transcription factors, HNF1A and HNF4G. In this study, we found that expres…
View article: Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer Open
Metastatic prostate cancer (mPC) is a clinically and molecularly heterogeneous disease. While there is increasing recognition of diverse tumor phenotypes across patients, less is known about the molecular and phenotypic heterogeneity prese…
View article: Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer
Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer Open
Recent clinical trials have explored the combination of androgen receptor (AR) pathway inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors as a potential treatment for castration-resistant prostate cancer. This combination treatm…
View article: An integrated proteomic portrait of prostate cancer progression
An integrated proteomic portrait of prostate cancer progression Open
Cancer forms a local tumor that subsequently metastasizes to distant organs. In prostate cancer, the latter part of the trajectory is influenced by the inhibition of the androgen receptor (AR). The study of proteomic changes along disease …
View article: PROX1 is an early driver of lineage plasticity in prostate cancer
PROX1 is an early driver of lineage plasticity in prostate cancer Open
Lineage plasticity is recognized as a critical determinant of lethality and resistance to AR pathway inhibitors in prostate cancer. Lineage plasticity is a continuum, ranging from AR activity-low tumors, AR-null tumors that do not express …
View article: Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants Open
The emergence of ARv567es via gene rearrangements causes transcriptional reprogramming and therapy resistance. This highlights ARv567es as a potential as a marker to guide treatment decisions.
View article: Supplementary Figure S4 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Figure S4 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone Open
Figure S4. Quantification of bone mineral density in mouse tibia specimen after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination increased bone mineral density (BMD) of the tibiae to a similar extent as d…
View article: Supplementary Figure S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Figure S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone Open
Figure S1. The levels of murine serum GAS6 before treatment in the LuCaP 147 PDX model. There were no significant differences in murine serum GAS6 levels among groups detected by ELISA
View article: Supplementary Figure S6 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Figure S6 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone Open
Figure S6. IHC staining (continuing Fig. 6A) demonstrates batiraxcept alone or in combination with docetaxel reduced p-ERK1/2 protein levels compared to vehicle-treated controls in intratibial LuCaP 147CR PDX model while total AKT proteins…
View article: Data from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Data from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone Open
Purpose:After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survi…
View article: Supplementary Figure S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Figure S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone Open
Figure S2. Batiraxcept and docetaxel alone or in combination significantly inhibited bone tumor growth and metastasis in LuCaP mPCa AC PDX models. A-B, Representative images of Masson-Goldner staining and Ku70 IHC of PDX cells in the tibia…
View article: Supplementary Figure S5 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Figure S5 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone Open
Figure S5. Mouse body weight change (%) after treatment for 30 days. None of the treatment groups displayed significant differences in body weight, indicating overall low toxicity from batiraxcept and docetaxel at the doses administered.
View article: Supplementary Figure S3 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Figure S3 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone Open
Figure S3. Mouse serum PSA after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination significanty reduced mouse serum PSA detected by ELISA.
View article: Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone Open
Patient cohort
View article: Supplementary Table S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Table S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone Open
Primary antibodies used for immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB)